Core Viewpoint - Axsome Therapeutics has reached a settlement with Alkem Laboratories regarding patent litigation over its product SUNOSI, allowing Alkem to market a generic version under specific conditions starting in 2040 [1][2]. Group 1: Settlement Agreement - Axsome will grant Alkem a license to sell a generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted, or on or after March 1, 2040, if not [1]. - The settlement is a result of Alkem's submission of an Abbreviated New Drug Application to the FDA for a generic version of SUNOSI [1]. Group 2: Regulatory Review - The settlement agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice for review as required by law [2]. - Axsome is also involved in similar patent litigation against another party related to SUNOSI, which remains pending in the U.S. District Court for the District of New Jersey [2]. Group 3: Company Overview - Axsome Therapeutics focuses on treating central nervous system disorders and has a portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness, and migraines [3]. - The company aims to address significant gaps in care and develop differentiated products to improve patient outcomes [3].